March 28th 2025
Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.
Study: Zithromax associated with cardiovascular deaths; FDA reviewing
May 18th 2012FDA has notified healthcare professionals that it is aware of a study published in the New England Journal of Medicine reporting a small increase in cardiovascular deaths and in the risk of death from any cause in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug.
Warfarin, aspirin similar in treating heart failure
May 17th 2012Warfarin fared no better than aspirin at reducing the combined risk of brain hemorrhage, stroke, or death for heart-failure patients in normal rhythm, according to the results of a study published in the New England Journal of Medicine.
Variation in schizophrenia treatment
May 17th 2012Patients with schizophrenia who switched from haloperidol decanoate or fluphenazine decanoate to risperidone microspheres discontinued their treatment more frequently, according to a new study published in the March issue of the Journal of Clinical Psychiatry.
Study on schizophrenia deaths makes surprising find
May 17th 2012A unique study designed to gauge the impacts of polypharmacy on schizophrenia mortality produced some surprising results: The use of antidepressants or 2 or more antipsychotics was not associated with increased deaths, but the use of benzodiazepine was.
Vitamin D threshold varies with season, study shows
May 17th 2012Researchers from the University of Washington have identified a threshold concentration of serum 25-hydroxyvitamin D [25-(OH)D] that is associated with increased risk for major medical events and they say that season-specific targets may be more appropriate than static targets when evaluating health risk.
Improved medication adherence: A growing movement in search of a leader
May 15th 2012There are many forces in play that can and should "converge to support better medication management and improved adherence," according to Tom Hubbard of the New England Healthcare Institute (NEHI), but coordination and leadership will be crucial.
Hospira recalls one lot of hydromorphone injection
May 14th 2012Hospira is voluntarily recalling one lot of hydromorphone injection, USP, 1 mg/mL (C-II), 1-mL fill in 2.5-mL Carpuject, NDC 0409-1283-31, after complaints that a single Carpuject contained more than the 1-mL labeled fill volume, according to a press release posted on the FDA website.